6LJ0 Stock Chart & Stats
€0.05
>-€0.01(-14.52%)
At close: 4:00 PM EST
€0.05
>-€0.01(-14.52%)
Day’s Range― - ―
52-Week Range€0.05 - €0.05
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€2.29M
Enterprise Value€1.94
Total Cash (Recent Filing)€761.00K
Total Debt (Recent Filing)€6.00K
Price to Earnings (P/E)―
BetaN/A
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding14,692,796
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.66
Price to Sales (P/S)0.00
P/FCF Ratio-0.46
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Minimal LeverageTTM debt is about $6K and debt-to-equity is near zero, limiting solvency pressure and preserving flexibility while the company funds its clinical-stage activities. Low leverage reduces fixed financial obligations and avoids adding interest burden to an already loss-making model.
Improving Loss And Burn ProfileTTM net loss of about $7.3M and cash burn of about $6.4M improved from 2023–2025 levels. Although still negative, a lower burn rate can create a more manageable base for financing or operational transition over the next several quarters.
Asset MonetizationThe sale of the Nanotechnologies subsidiary, including MAT2203 and the LNC platform, provides $4M upfront, potential milestones and mid-single-digit royalties. This creates a defined monetization path for these assets and could provide resources during the company’s strategic transition.
Bears Say
NYSE Listing Compliance RiskNYSE American’s compliance notice highlights sustained losses and stockholders’ equity of only $1.8M, with potential delisting if the remediation plan fails. Continued listing therefore depends on restoring capital compliance, adding structural uncertainty to financing access and investor participation.
Pre-Commercial Operating ModelThe company has no meaningful recent revenue while continuing to report a substantial net loss, confirming that its business model remains pre-commercial. Without a sustainable revenue base, operating leverage is unavailable and future progress depends on successful development, transactions or external funding.
Persistent Cash ConsumptionOperating and free cash flow remain firmly negative at approximately $6.4M each on a trailing basis, despite improvement from prior years. Continued cash consumption requires additional funding or a successful strategic transition, which can constrain investment choices and increase dilution pressure.
Matinas BioPharma News
6LJ0 FAQ
What was Matinas BioPharma’s price range in the past 12 months?
Matinas BioPharma lowest stock price was €0.05 and its highest was €0.05 in the past 12 months.
What is Matinas BioPharma’s market cap?
Matinas BioPharma’s market cap is €2.29M.
When is Matinas BioPharma’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Matinas BioPharma’s earnings last quarter?
Currently, no data Available
Is Matinas BioPharma overvalued?
According to Wall Street analysts Matinas BioPharma’s price is currently Overvalued.
Does Matinas BioPharma pay dividends?
Matinas BioPharma does not currently pay dividends.
What is Matinas BioPharma’s EPS estimate?
Matinas BioPharma’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Matinas BioPharma have?
Matinas BioPharma has 14,692,796 shares outstanding.
What happened to Matinas BioPharma’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Matinas BioPharma?
Currently, no hedge funds are holding shares in DE:6LJ0
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Matinas BioPharma
Matinas BioPharma Holdings, Inc. is a biopharmaceutical firm in the clinical development phase, dedicated to identifying and advancing a range of potential therapeutic products. The company's innovative Lipid Nanocrystal (LNC) platform technology underpins its product development efforts. This sophisticated LNC delivery system leverages lipid nano-crystals to transport a diverse array of therapeutic agents, including small molecules, nucleic acids, gene therapies, vaccines, proteins, and peptides. Its primary experimental drug, LYPDISO, is a proprietary, prescription-grade omega-3 free fatty acid compound engineered to address cardiovascular and metabolic disorders. Matinas BioPharma is also advancing MAT2203, an orally administered version of amphotericin B. This candidate is currently in Phase II clinical trials, where it is being evaluated for its ability to prevent invasive fungal infections in patients undergoing immunosuppressive treatment. Furthermore, MAT2501, an oral formulation of the broad-spectrum aminoglycoside antibiotic amikacin, has successfully completed Phase I clinical trials. Its aim is to combat a spectrum of multidrug-resistant bacterial infections, such as non-tuberculous mycobacterium, multidrug-resistant gram-negative, and intracellular bacterial pathogens. The company actively engages in collaborations, including a research partnership with the National Institute of Allergy and Infectious Diseases (NIAID) to further the development of Gilead's antiviral drug, remdesivir. Additionally, it has a feasibility collaboration with Genentech, Inc. focused on creating new oral drug formulations. Established in 2013, Matinas BioPharma maintains its corporate headquarters in Bedminster, New Jersey.